J Jaime | PubMed Health

PubMed2000

A method for detecting antibody internalization in drug targeting.

BCM43/2E5 monoclonal antibody with a specificity for human ovarian carcinoma was evaluated for its binding and internalization behaviour on both fixed and live cells. Internalization of this antibody by the targeted cells was demonstrated by ELISA, flow cytometry and immunoperoxidase. At reduced temperatures or in the presence of electron transfer blockers, internalization of bound antibody was prevented. This method is rapid and reproducible and may be used efficiently for the selection of antibodies suitable for drug targeting in cancer therapy.

3T3 Cells↗

PubMedDate not supplied

Paclitaxel immunoconjugate for the specific treatment of ovarian cancer in vitro.

A paclitaxel derivative was used for the preparation of a drug immunoconjugate for the specific targeting to ovarian cancer cells by the BCM43/2E5 monoclonal antibody. To determine the efficiency of conjugation we developed two reproducible immunoassays. Paclitaxel was detected on the conjugate by a paclitaxel immunoassay and the activity of the antibody was determined by a competition assay with BCM43/2E5 antibody. Paclitaxel-BCM43/2E5 immunoconjugate was tested on five human cell lines. This conjugate was cytotoxic for ovarian teratocarcinoma cells, ovarian adenocarcinoma and breast cancer cells, while the activity was negligible for normal cells. These results describe, for the first time, the synthesis of a soluble tumor specific- paclitaxel immunoconjugate which may establish a new mode for the use of this drug in cancer therapy for limiting side effects.

Antibodies, Monoclonal↗